A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia

References

• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev.6, 97–111 (2002).
   PubMed Web of Science ®Google Scholar
• Freeman HL. Is there a need for a para hypnotic ? Approaches to the co-diagnosis of insomnia and anxiety. J. Drug Dev. Clin. Pract.7, 289–302 (1996).
   Google Scholar
• Edinger JD, Fins AI, Glenn DM et al. Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints? J. Consult. Clin. Psychol.68, 586–593 (2000).
   PubMed Web of Science ®Google Scholar
• Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch. Intern. Med.158, 1099–1107 (1998).
   PubMed Web of Science ®Google Scholar
• Morin CM, Gramling SE. Sleep patterns and aging: comparison of older adults with and without insomnia complaints. Psychol. Aging4, 290–294 (1989).
   PubMed Web of Science ®Google Scholar
• Johnson LC, Spinweber CL. Good and poor sleepers differ in Navy performance. Mil. Med.148, 727–731 (1983).
   PubMed Web of Science ®Google Scholar
• Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med. Rev.10, 357–369 (2006).
   PubMed Web of Science ®Google Scholar
• Scott JP, McNaughton LR, Polman RC. Effects of sleep deprivation and exercise on cognitive, motor performance and mood. Physiol. Behav.87, 396–408 (2006).
   PubMed Web of Science ®Google Scholar
• Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose–response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep26, 117–126 (2003).
   PubMed Web of Science ®Google Scholar
• NIH. National Institutes of Health state-of-the-science conference statement: manifestations and management of chronic insomnia in adults. Sleep28, 1049–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Staner L. Insomnia comorbid with depression. Sleep Med. Rev.14, 35–46 (2010).
   PubMed Web of Science ®Google Scholar
• Mellinger GB, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Arch. Gen. Psychiatry42, 225–232 (1985).
   PubMed Web of Science ®Google Scholar
• Perlis ML, Smith MT, Cacialli DO, Nowakowski S, Orff H. On the comparability of pharmacotherapy and behavior therapy for chronic insomnia: commentary and implications. J. Psychosom. Res.54, 51–59 (2003).
   PubMed Web of Science ®Google Scholar
• Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur. J. Clin. Pharmacol.36, 461–466 (1989).
   PubMedGoogle Scholar
• Dingemanse J, Bury D, Hussain Y, van Giesbergen P. Comparative tolerability, pharmacodynamic and pharmacokinetic of a metabolite of quinolizinone hypnotic and zolpidem in healthy subjects. Drug Metab. Dispos.28, 1411–1416 (2000).
   PubMedGoogle Scholar
• Cope DW, Wulff P, Oberto A et al. Abolition of zolpidem sensitivity in mice with a point mutation in the GABAA receptor gamma2 subunit. Neuropharmacology47, 17–34 (2004).
   PubMedGoogle Scholar
• Cope DW, Halbsguth C, Karayannis T et al. Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation. Eur. J. Neurosci.21, 3002–3016 (2005).
   PubMedGoogle Scholar
• Sancar F, Ericksen SS, Kucken AM, Teissére JA, Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Mol. Pharmacol.71, 38–46 (2007).
   PubMedGoogle Scholar
• McKernan RM, Quirk K, Prince R et al. GABAA receptor subtypes immunopurified from rat brain with alpha subunit-specific antibodies have unique pharmacological properties. Neuron7, 667–676 (1991).
   PubMed Web of Science ®Google Scholar
• Pritchett DB, Seeburg PH. Gamma-aminobutyric acid A receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem.54, 1802–1804 (1990).
   PubMed Web of Science ®Google Scholar
• Ruano D, Vizuete M, Cano J, Machado A, Vitorica J. Heterogeneity in the allosteric interaction between the gamma-aminobutyric acid (GABA) binding site and three different benzodiazepine binding sites of the GABAA/benzodiazepine receptor complex in the rat nervous system. J. Neurochem.58, 485–493 (1992).
   PubMedGoogle Scholar
• Mertens S, Benke D, Mohler H. GABAA receptor populations with novel subunit combinations and drug binding profiles identified in brain by alpha 5- and delta-subunit-specific immunopurification. J. Biol. Chem.268, 5965–5973 (1993).
   PubMed Web of Science ®Google Scholar
• Maric D, Maric I, Wen X et al. GABAA receptor subunit composition and functional properties of Cl-channels with differential sensitivity to zolpidem in embryonic rat hippocampal cells. J. Neurosci.19, 4921–4937 (1999).
   PubMed Web of Science ®Google Scholar
• Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol.131, 1251–1254 (2000).
   PubMed Web of Science ®Google Scholar
• Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype function. Curr. Opin. Phramacol.6, 18–23 (2006).
   PubMed Web of Science ®Google Scholar
• Rowlett JK, Spealman RD, Lelas S. Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics. J. Pharmacol. Exp. Ther.291, 1233–1241 (1999).
   PubMedGoogle Scholar
• Rowlett JK, Spealman RD, Lelas S, Cook JM, Yin W. Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors. Psychopharmacology165, 209–215 (2003).
   PubMed Web of Science ®Google Scholar
• Mirza NR, Rodgers RJ, Mathiasen LS. Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination. Pharmacol. Exp. Ther.316, 1291–1299 (2006).
   PubMedGoogle Scholar
• Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl Acad. Sci. USA102, 915–920 (2005).
   PubMed Web of Science ®Google Scholar
• Mirza NR, Nielsen EØ. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? J. Pharmacol. Exp. Ther.316, 1378–1385 (2006).
   PubMedGoogle Scholar
• Blednov YA, Jung S, Alva H et al. Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs. J. Pharmacol. Exp. Ther.304, 30–36 (2003).
   PubMedGoogle Scholar
• de Almeida RM, Rowlett JK, Cook JM, Yin W, Miczek KA. GABAA/alpha1 receptor agonists and antagonists: effects on species-typical and heightened aggressive behavior after alcohol self-administration in mice. Psychopharmacology172, 255–263 (2004).
   PubMed Web of Science ®Google Scholar
• McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci.19, 139–143 (1996).
   PubMed Web of Science ®Google Scholar
• Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci.24, 726–731 (2001).
   PubMed Web of Science ®Google Scholar
• Szymusiak R, McGinty D. Hypothalamic regulation of sleep and arousal. Ann. NY Acad. Sci.1129, 275–286 (2008).
   PubMedGoogle Scholar
• Haas H, Panula P. The role of histamine and the tuberomammilary nucleus in the nervous system. Nat. Rev. Neurosci.4, 121–130 (2003).
   PubMed Web of Science ®Google Scholar
• Sergeeva OA, Erikson KS, Sharanova IN, Vorobjev VS, Haas HL. GABA(A) receptor heterogeneity in histaminergic neurons. Eur. J. Neurosci.16, 1472–1482 (2002).
   PubMedGoogle Scholar
• Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M. The sedative component of anaesthesia is mediated by GABA(A) receptors in endogenous sleep pathway. Nat. Neurosci.5, 979–984 (2002).
   PubMed Web of Science ®Google Scholar
• Kopp C, Rudolph U, Tobler I. Sleep EEG changes after zolpidem in mice, Neuroreport15, 2299–2302 (2004).
   PubMed Web of Science ®Google Scholar
• Steriade M. Brain electrical activity and sensory processing during wake and sleep states. In: Principles and Practice of Sleep Medicine, 4th Edition. Kryger MH, Roth T, Dement WC (Eds). Elsevier Sauders, Philadelphia, PA, USA, 101–119 (2005).
   Google Scholar
• Jia F, Goldstein PA, Harrison NL. The modulation of synaptic GABAA receptors in the thalamus by eszopiclone and zolpidem. J. Pharmacol. Exp. Ther.328, 1000–1006 (2009).
   PubMed Web of Science ®Google Scholar
• Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs59, 865–889 (2000).
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs19, 65–89 (2005).
   PubMed Web of Science ®Google Scholar
• Thénot JP, Hermann P, Durand A. Pharmacokinetics and metabolism of zolpidem in various animal species and in man. In: Imidazopyridines In Sleep Disorders: A Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 21–23 (1988).
   Google Scholar
• Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet.43, 227–238 (2004).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Legagneux E, Harmatz JS et al. Dynamics and kinetics of a modified-release formulation of zolpidem. Comparison with immediate-release standard zolpidem and placebo. J. Clin. Pharmacol.46, 1469–1480 (2006).
   PubMed Web of Science ®Google Scholar
• Fraisse J, Garrigou-Gadenne D, Thénot JP. Pharmacokinetic and metabolic profiles of zolpidem. In: Zolpidem: An Update of its Pharmacological Properties and Therapeutic Place in The Management of Insomnia. Freeman H, Puech AJ, Roth T (Eds). Elsevier, Paris, France, 45–57 (1996).
   Google Scholar
• Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs17, 513–532 (2003).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, von Moltke LL et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J. Pharmacol. Exp. Ther.293, 435–443 (2000).
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, von Moltke LL et al. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J. Clin. Pharmacol.42, 1142–1146 (2002).
   PubMedGoogle Scholar
• Olubodun JO, Ochs HR, von Moltke LL et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br. J. Clin. Pharmacol.56, 297–304 (2003).
   PubMed Web of Science ®Google Scholar
• Monti JM, Pandi-Perumal SR, Langer SZ. Zolpidem: its use in the treatment of sleep disorder. In: Sleep Disorders, Diagnosis and Therapeutics. Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ (Eds). Informa Healthcare, London, UK, 295–323 (2008).
   Google Scholar
• Scharf MB, Roth T, Vogel GB, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J. Clin. Psychiatry55, 192–199 (1994).
   PubMed Web of Science ®Google Scholar
• Monti JM, Monti D, Estévez F, Giusti M. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int. Clin. Psychopharmacol.11, 255–263 (1996).
   PubMed Web of Science ®Google Scholar
• Wheatley D. Zolpidem: a new imidazopyridine hypnotic. Psychopharmacol. Bull.25, 124–127 (1989).
   PubMedGoogle Scholar
• Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double blind, placebo-controlled clinical trial. Clin. Neuropharmacol.19, 333–340 (1996).
   PubMed Web of Science ®Google Scholar
• Lahmeyer H, Wilcox CS, Kann J. Subjective efficacy of zolpidem in outpatients with chronic insomnia. Clin. Drug Invest.13, 134–144 (1997).
   Web of Science ®Google Scholar
• Hermann WM, Dubicki S, Wober W. Zolpidem: a four week pilot polysomnographic study in patients with chronic sleep disturbances. In: Imidazopyridines in Sleep Disorders : a Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 261–278 (1988).
   Google Scholar
• De Roeck JMJ, Cluydts RJG. A polysomnographic study of short-term treatment with zolpidem in chronic psychophysiological insomnia. In: Stilnox, Proceedings of the 1st Imidazopyridine Symposium. Kurtz D, Monti JM (Eds). Adis International, New Delhi, India, 34–42 (1991).
   Google Scholar
• Staner L, Demazières A, Luthringer R. Use of psychotropic drugs in the elderly: effects on sleep architecture. In: Principles and Practice of Geriatric Sleep Medicine. Pandi-Perumal SR, Monti J, Monjan AW (Eds). Cambridge University Press, Cambridge, UK, 371–383 (2010).
   Google Scholar
• Uchimura N, Nakajima T, Hayash K et al. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized cross-over comparative study with brotizolam. Prog. Neuropsychopharmacol. Biol. Psychiatry30, 22–29 (2006).
   PubMed Web of Science ®Google Scholar
• Dolenc L, Vujić D, Vodušek DB, Henigsberg N, Demarin V, Kocemba J. Multicenter double-blind study of zolpidem and triazolam in treatment of chronic insomnia in elderly. Sleep21(Suppl. 1), 135 (1998).
   Google Scholar
• Leger D, Roger M, Gerard D. [Sleep and life rhythm in a population of elderly insomniacs]. Revue de Gériatrie23, 73–84 (1998).
   Google Scholar
• Walsh JK, Erman M, Erwin CW et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacol.3, 191–198 (1998).
   Google Scholar
• Schadeck B, Chelly M, Ansellem D, Cohen A, Peraudeau P, Scheck F. [Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) in the treatment of insomnia : a placebo-controlled study]. Sem. Hop.72, 428–439 (1996).
   Google Scholar
• Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia – a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry27, 166–175 (1994).
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic effectively treats insomnia in elderly patients without causing rebound effects. Prim. Care CompanionJ. Clin. Psychiatry1, 114–120 (1999).
   Google Scholar
• Leppik I, Roth-Schecheter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev. Res.40, 230–238 (1997).
   Web of Science ®Google Scholar
• Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J. Int. Med. Res.26, 13–24 (1998).
   PubMedGoogle Scholar
• Hajak G, Cluydts R, Declerck A et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int. Clin. Psychopharmacol.17, 9–17 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh JK, Roth T, Randazzo A et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep23, 1087–1096 (2000).
   PubMed Web of Science ®Google Scholar
• Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J. Clin. Psychiatry65, 1128–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Allain H, Arbus L, Schück S. Efficacy and safety of zolpidem administered ‘as needed’ in primary insomnia: results of a double-blind, placebo-controlled study. Clin. Drug Invest.21, 391–400 (2001).
   Google Scholar
• Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behaviour therapy and pharmacotherapy for insomnia. A randomized controlled trial and direct comparison. Arch. Int. Med.164, 1888–1896 (2004).
   PubMed Web of Science ®Google Scholar
• Morin CM, Vallières A, Guay B et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA301, 2005–2015 (2009).
   PubMed Web of Science ®Google Scholar
• Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep31, 1277–1284 (2008).
   PubMed Web of Science ®Google Scholar
• Caille G, Spenard J, Lacasse Y. Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. Biopharm. Drug. Dipos.4, 31–42 (1983).
   PubMed Web of Science ®Google Scholar
• Fuji I. Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers. J. Pharmacobiodyn.11, 206–209 (1988).
   PubMedGoogle Scholar
• Staner L, Eriksson M, Cornette F et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med.10, 616–620 (2008).
   PubMed Web of Science ®Google Scholar
• Staner C, Joly F, Jacquot N et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr. Med. Res. Opin.26, 1423–1431 (2010).
   PubMed Web of Science ®Google Scholar
• Palminteri R, Narbonne G. Safety profile of zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 351–361 (1988).
   Google Scholar
• Pringuey D, Sallière D. Tolerability and safety of zolpidem. In: Zolpidem: An Update of its Pharmacological Properties and Therapeutic Place in The Management of Insomnia. Freeman H, Puech AJ, Roth T (Eds). Elsevier, Paris, France, 195–214 (1996).
   Google Scholar
• Terzano MG, Milioli G, De Paolis D, Parrino L. Z-drugs: comparative tolerability. In: Sleep Disorders, Diagnosis and Therapeutics. Informa Healthcare, London, UK, 364–378 (2008).
   Google Scholar
• Ahrens J. [Treatment of sleep disorder with zolpidem, a drug without dependence potential]. Therapiewoche Schweiz9, 660–662 (1993).
   Google Scholar
• Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol.23, 54–58 (2000).
   PubMed Web of Science ®Google Scholar
• Coleman DE, Ota K. Hallucinations with zolpidem and fluoxetine in an impaired driver. J. Forensic Sci.49, 392–393 (2004).
   PubMedGoogle Scholar
• Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: a possible interaction. Int. Psychogeriatr.18, 749–751 (2006).
   PubMed Web of Science ®Google Scholar
• Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J. Toxicol. Clin. Toxicol.36, 195–203 (1998).
   PubMed Web of Science ®Google Scholar
• Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs22, 1021–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med. Rev.1, 97–108 (1997).
   PubMedGoogle Scholar
• Riemann D, Spiegelhalder K, Feige B et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med. Rev.14(1), 19–31 (2010).
   PubMed Web of Science ®Google Scholar
• Pigeon WR, Perlis ML. Sleep homeostasis in primary insomnia. Sleep Med. Rev.10, 247–254 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider-Helmert D. Twenty-four-hour sleep-wake function and personality patterns in chronic insomniacs and healthy controls. Sleep10, 452–462 (1987).
   PubMed Web of Science ®Google Scholar
• Stepanski E, Zorick F, Roehrs T, Young D, Roth T. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep11, 54–60 (1988).
   PubMed Web of Science ®Google Scholar
• Regestein QR, Dambrosia J, Hallett M, Murawski B, Paine M. Daytime alertness in patients with primary insomnia. Am. J. Psychiatry150, 1529–1534 (1993).
   PubMed Web of Science ®Google Scholar
• Fleming J, Moldofsky H, Walsh JK, Scharf M, Nino MG, Radonjic D. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin. Drug Invest.9, 303–313 (1995).
   Web of Science ®Google Scholar
• Dujardin K, Guieu JD, Leconte-Lambert C, Leconte P, Borderies P, de La Giclais B. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated insomniacs. Pharmacopsychiatry31, 14–18 (1998).
   PubMedGoogle Scholar
• Staner L, Ertle S, Boeijinga P et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology181, 790–798 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeeren A, O’Hanlon JF, Declerck AC, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther.21, 47–64 (1995).
   Google Scholar
• Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med.4, 553–561 (2003).
   PubMedGoogle Scholar
• Otmani S, Demazières A, Staner C et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol.23, 693–705 (2008).
   PubMed Web of Science ®Google Scholar
• Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J. Int. Med. Res.20, 162–170 (1992).
   PubMed Web of Science ®Google Scholar
• Schlich D, L’Heritier C, Coquelin JP, Attali P, Kryrein HJ. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J. Int. Med. Res.19, 271–279 (1991).
   PubMed Web of Science ®Google Scholar
• Scharf MB, Mendels J, Thorpy M, Weiss B. Safety of long-term zolpidem treatment in patients with insomnia. Curr. Ther. Res.55, 1100–1111 (1994).
   Google Scholar
• Hajak G, Bandelow B, Zulley J, Pittrow D. ‘As needed’ pharmacotherapy combined with stimulus control treatment in chronic insomnia – assessment of a novel intervention strategy in a primary care setting. Ann. Clin. Psychiatry14, 1–7 (2002).
   PubMedGoogle Scholar
• Levy P, Massuel MA, Gerard DA. ‘As-needed’ prescription of zolpidem for insomnia in routine general practice. Clin. Drug Invest.24, 625–632 (2004).
   PubMedGoogle Scholar
• Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int. Clin. Psychopharmacol.14, 287–303 (1999).
   PubMed Web of Science ®Google Scholar
• Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs60, 413–445 (2000).
   PubMed Web of Science ®Google Scholar
• Erman MK, Zammit G, Rubens R et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J. Clin. Sleep Med.4, 229–234 (2008).
   PubMed Web of Science ®Google Scholar
• Ware CJ, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin. Neuropharmacol.20, 116–125 (1997).
   PubMed Web of Science ®Google Scholar
• Silvestri R, Ferrillo F, Murri L et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum. Psychopharmacol.11, 225–233 (1996).
   Google Scholar
• Oude Voshaar RC, van Balkom AJLM, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur. Neuropsychopharmacol.14, 301–306 (2004).
   PubMedGoogle Scholar
• Roger M, Attali P, Coquelin J-P. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin. Ther.15, 127–136 (1993).
   PubMedGoogle Scholar
• Parrino L, Smerieri A, Giglia F, Milioli G, De Paolis F, Terzano MG. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin. Neuropharmacol.31, 40–50 (2008).
   PubMedGoogle Scholar
• Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction98, 1371–1378 (2003).
   PubMed Web of Science ®Google Scholar
• Lemoine P, Allain H, Janus C, Sutet P. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur. Psychiatry10(Suppl. 3), 161S–165S (1995).
   PubMedGoogle Scholar
• Ganzoni E, Santoni JP, Chevillard V, Sébille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J. Int. Med. Res.23, 61–73 (1995).
   PubMed Web of Science ®Google Scholar
• Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int. Clin. Psychopharmacol.13, 157–167 (1998).
   PubMed Web of Science ®Google Scholar
• Ganzoni E, Gugger M. Safety profile of zolpidem: two studies in 3805 patients with Swiss practitioners. Schweiz. Rundsch. Med. Prax.88, 1120–1127 (1999).
   Google Scholar
• Danjou P, Paty I, Fruncillo R et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br. J. Clin. Pharmacol.48, 367–374 (1999).
   PubMed Web of Science ®Google Scholar
• Tsutsui S; Zolpidem Study Group. A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia. J. Int. Med. Res.29, 163–177 (2001).
   PubMedGoogle Scholar